Aquapharm Biodiscovery discovers novel antibiotic compound

Monday, August 6, 2012 11:01 AM

Aquapharm Biodiscovery, a Scottish marine biotechnology company, has made a discovery in the development of next-generation antibiotics.

The firm has discovered a new antibiotic compound thought to be effective against a broad spectrum of multi-drug resistant bacteria, including multi-drug resistant Staphylococcus Aureus (MDRSA) and multi-drug resistant Streptococcus pneumoniae (MDRSP), Clostridium difficile and Enteroccocus faecalis.

The compound, AQP-182, is one of a number of druggable new molecules identified by Aquapharm from its collection of more than 10,000 marine micro-organisms. Scientists screened a fraction of the collection to look for micro-organisms which may have anti-infective and anti-inflammatory properties—and discovered 16 compounds with potent pharmacological potential.

Five new chemical entities, including AQP-182, are now in preclinical development at Aquapharm for the treatment of bacterial infections resistant to existing therapies.

“We are very pleased with the output of our drug discovery platform based on marine microorganisms,” said Dr. Tim Morley, CSO of Aquapharm. “From an initial screening of a small portion of our natural product library we have identified 16 novel compounds belonging to totally novel and diverse chemical classes. The most advanced compound AQP-182 has a promising pharmacological and pharmacokinetic profile which is extremely relevant for the treatment of hard to treat resistant bacterial infections”.

Initial in vivo studies of AQP-182 suggest greater potency than the current “best-in-class” drug used against MDRSA, and Aquapharm's experts believe it could have the potential for once-a-day dosing.

A phase I clinical trial is expected in the second half of 2013.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private á¼€nancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs